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Abstract
Background: Alternative splicing (AS) is an important regulatory mechanism for gene expression
and protein diversity in eukaryotes. Previous studies have demonstrated that it can be causative
for, or specific to splicing-related diseases. Understanding the regulation of AS will be helpful for
diagnostic efforts and drug discoveries on those splicing-related diseases. As a novel exon-centric
microarray platform, exon array enables a comprehensive analysis of AS by investigating the
expression of known and predicted exons. Identifying of AS events from exon array has raised
much attention, however, new and powerful algorithms for exon array data analysis are still absent
till now.
Results: Here, we considered identifying of AS events in the framework of variable selection and
developed a regression method for AS detection (REMAS). Firstly, features of alternatively spliced
exons were scaled by reasonably defined variables. Secondly, we designed a hierarchical model
which can represent gene structure and transcriptional influence to exons, and the lasso type
penalties were introduced in calculation because of huge variable size. Thirdly, an iterative two-step
algorithm was developed to select alternatively spliced genes and exons. To avoid negative effects
introduced by small sample size, we ranked genes as parameters indicating their AS capabilities in
an iterative manner. After that, both simulation and real data evaluation showed that REMAS could
efficiently identify potential AS events, some of which had been validated by RT-PCR or supported
by literature evidence.
Conclusion: As a new lasso regression algorithm based on hierarchical model, REMAS has been
demonstrated as a reliable and effective method to identify AS events from exon array data.
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Background
Alternative splicing (AS) is an important regulatory mech-
anism in eukaryotes to increase proteome diversity by
allowing the production of multiple isoforms from a sin-
gle gene. It is one of the most extensive phenomena that
account for complexity of molecular function through the
combination of splice sites. Many AS events can modulate
protein function and structure by gain or loss of domains
coded by alternatively spliced exons [1]. At the same time,
the disrupted code and machinery of splicing have roles in
various diseases, e.g. cystic fibrosis, type I diabetes and
myocardial infarction [2]. Therefore, genome-wide explo-
ration of AS events will pave the way for future attempts
to develop novel therapy strategies for diseases caused by
AS [3].
Besides the assembly of cDNA sequences and expressed
sequence tags (ESTs) to predict AS events [4], high-
throughput microarray techniques had been widely used
to identify AS events in genome-wide [5]. Clark et al.
designed an oligonucleotide-spotted array probing at
intron-exon junction to distinguish spliced RNA from
unspliced ones and study the influences on splicing by
eliminating the effects of splicing factors [6]. Yeakley et al.
developed a novel bead-based fiber optic array with high
sensitivity to perform a parallel analysis of mRNA iso-
forms in human [7]. Johnson et al. designed a splicing
array monitoring exon-exon junctions of human RefSeq
mRNAs in 52 tissues and cell lines [8]. Pan et al. combined
information from six probes (half of them for exon-exon
junctions and the rest for exon bodies) to quantitatively
identify tissue-specific AS in mammalian cells [9]. Ule et
al. customized a kind of microarray with probes targeting
exon bodies and junctions to investigate the function of a
neuron-specific splicing factor [10]. Conclusively, these
microarrays are capable to distinguish the exon architec-
ture of transcript variants. However, they are limited to
interrogate predetermined exons and exon junctions with
restricted resolution.
Affymetrix recently published a high density exon-centric
microarray, GeneChip@ Exon 1.0 ST Array, which covers a
high density of exon regions with roughly 40 probes per
gene and altogether over 5.5 million features on each
array (see GeneChip@ Exon Array Design Technical Note,
Affymetrix). Exon array can identify AS events and
uncover novel exons by probing all known and predicted
exon regions. For the first time, both gene-level and exon-
level expression can be studied in genome-wide with a
single array, which promote understanding both tran-
scription and splicing regulation.
Methods for detecting AS events from microarray data
have been studied to address different platforms or analy-
sis steps [11-13]. However, algorithm focusing on inden-
tifying AS from Affymetrix exon array is still lacking. Since
there are few substantially validated AS datasets for exon
array, it is challenging to develop and evaluate an effective
prediction algorithm with few false positives. "Splicing
Index" (SI), a basic linear model for estimating changes of
exon expression, is most widely used in identification of
AS from exon array [14-16]. Xing et al. also introduced a
novel probe selection strategy for gene signal estimation
to eliminate opposite effects introduced by alternatively
spliced exons[17]. A program named 'GeneBASE' was
then developed based on the probe selection strategy and
a probe-specific background correction procedure [18].
However, new and powerful methods to identify AS other
than SI model are still necessary.
In this study, we utilized a shrinkage and selection strategy
for linear regression based on improved "lasso"
method[19] to select alternatively spliced genes and
exons. Parameter and variable indicating splicing capabil-
ity are defined to quantitatively scale the features of AS
events. By controlling the splicing parameters in the
regression model, AS events can be selected from numer-
ous candidates and ranked by confidence. Simulations
and real data evaluation suggest that REMAS is reliable
and effective to identify AS events from exon array data.
Methods
Firstly, we used a linear formula to model gene structure
with exons. We suppose there are K genes on chip of exon
array, and the ith gene has pi exons. Logarithmic values of
probe sets signals after normalization and estimation by
PLIER (see Probe Logarithmic Intensity Error Estimation
Technical Note, Affymetrix) algorithm are taken as expres-
sion of exon. "exoni, j" denotes expression of the jth exon in
the ith gene. We define variable xi, j titled with 'AS Indica-
tor' (ASI) as following:
The intuition behind is that intensities of constitutive
exons (relative to alternatively spliced exons) are strongly
correlated to the overall gene expression. Thus ASI is con-
sidered as the expression difference between alternatively
spliced exon and dominant constitutive exons and low-
weighted effects introduced by AS can be reduced by
median function to estimate a more accurate value of
gene. Normally, the absolute value of ASI is close to zero
for constitutive exon and much larger than zero for alter-
natively spliced exon.
We regard the class label as the response variable in our
regression model, and denote it using y. A basic regression
model can be applied to feature the relationship between
ASI and y:
x exon median exon ij ij jp ij i ,, , , =− {} ∈{} 1" (1)BMC Bioinformatics 2009, 10(Suppl 1):S18 http://www.biomedcentral.com/1471-2105/10/S1/S18
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We primarily focus on the coefficients βi, j in formula (2).
The larger the absolute value of coefficient βi,  j, the
stronger the potentials for AS events. Furthermore, we
decompose βi, j into two parameters αi and θi, j represent-
ing effects from gene level and exon level respectively as
following:
βi, j = αi·θi, j (3)
The parameter αi (αi > 0) is a positive real number meas-
uring the regulatory influence to exon from gene level.
The gene level regulation from alternatively spliced gene is
different from constitutively spliced genes, so that affected
exons can be inferred by the value distribution of αi. After
then, a particular θi, j, which is used to infer the influence
from exon level indicating the alternatively spliced exon
and its position in the gene. Based on this idea, formula
(2) can be transformed to:
Note that by location transformation, we can always
assume that the predictors and the response have mean 0,
so we can ignore the intercept in equation (4)
For real exon array data, the number of variables is quite
huge (up to several millions), while the number of sam-
ples is small (usually less than 100). Therefore, the varia-
ble selection procedure is absolutely necessary for the
regression model, which uses the theory of "lasso" for ref-
erence. The restraint for L1 norm is introduced to perform
the variable selection. Regression in REMAS still has a
good performance when sample size is much less than
number of variables because of the L1 penalty. In practice,
two parameters t1 and t2 are set as certain thresholds to
restrict the following L1 constraints.
If variables don't indicate AS events between samples, the
corresponding coefficients would converge to zero. This
procedure is equivalent to the minimization of the loss
function below.
μ and ν are two fine-tuning parameters in the formula
above, where μ controls the estimation of parameter αi for
gene level while ν controls the estimation of parameter θi,
j for exon level. These hierarchical controls are not compli-
cated to tune in practice because the two parameters μ and
ν can be simplified into one parameter as λ = μ·ν. Subse-
quently, we can show that minimization of equation (5)
is equivalent to the minimization of following loss func-
tion,
Here the equivalence is used to mean that the final fitted
βi, j from equation (5) and equation (6) are the same,
although they may corresponding to different αi and θi, j .
Thus we only need to tune one parameter λ. In practice,
the parameter λ is set in advance before the optimization.
We used a cross-validation method to obtain a suitable λ
on performance.
A two-step iterative way is applied to estimate the param-
eter α and θ in the regression. For example, θ is initialized
as constant to estimate α; then α is set as constant and θ is
updated by minimizing the loss function in the same way.
Actually, each procedure in the iteration is a typical 'lasso'
problem as described in classical "lasso" algorithm[19].
Since some true AS events can't be selected out when the
sample size is small, we introduce a complementary
improvement by ranking the selected genes based on the
parameter α. Genes with high potential of AS are selected
first and then classified into group I, and other genes are
temporally classified into group II. After removing exons
of group I gene, the iterative procedure is carried out to
sort the rest of genes, and a most potent gene can be
selected out from group II again. After the iterative selec-
tion, genes in group I (alternatively spliced genes) can be
globally ranked by the parameter α. It is accepted that
genes ranking high are more potential to undergo AS.
Results
In order to evaluate the accuracy and sensitivity of REMAS,
simulation covering a diversity of sample sizes, AS types
and regulatory patterns are performed and a real exon
array dataset interpreting colon cancer was used to do the
test [16]. Alternatively spliced exons predicted by the
above mentioned SI algorithm are compared with predic-
tion of REMAS.
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Evaluation on simulated data
Previous study has reported that probesets targeting those
constitutive exons are strongly correlated across various
samples[17]. Multiple normal distributions with proper
covariance were used to simulate these constitutive exons
as follows.
Three different simulations were designed to evaluate the
performance of REMAS on different scenarios. For each
evaluation, two sources of samples (e.g. treatment group
and control group) are designed for comparison. There
are 50 genes containing 10 exons each in each sample.
Simulation 1
As shown in Table 1, we designed 100 samples for both
groups, and 4 genes are alternatively spliced genes in each
sample. For alternatively spliced gene 1 and 2, exon 5 and
exon 6 were defined as "cassette" exons (a kind of splicing
type with a form of exon skipping or inclusion) in treat-
ment group. For alternatively spliced gene 3 and 4, exon 5
and exon 6 were simulated as mutually exclusive exons, in
the sense that only one exon is included in the mature
mRNA in a tandem array of alternative exons [20]. These
splicing patterns were simulated by different normal dis-
tributions for comparison (see Table 1). However, consti-
tutive exons are uniformly set as highly correlated normal
distributions.
Given a specific λ, we performed a five-fold cross-valida-
tion to measure the accuracy of prediction. The optimal λ
= 0.5 was concluded from 500 different runs. For the tun-
ing parameter λ = 0.5, we simulated 1000 times to select
genes and exons undergoing AS. As illustrated in Figure 1
Results of simulation 1a, four simulated alternatively
spliced genes have extremely high frequencies to be
selected out, while other 46 genes are on the contrary.
Obviously, REMAS is an effective discriminator for selec-
tion of alternatively spliced genes. Figure 1b shows the
property of θ for the first 50 exons in selection. The left
were ignored in the panel because they have uniform
expression as constitutive exons. Y-axis describes the aver-
age values of θi, j for 1000 times of selection. It is con-
cluded that the absolute value of average θi,  j  for
alternatively spliced exons are significantly higher than
constitutive exons. Average value of θi,  jproportionally
changes following the power of normal distribution (see
Figure 1b and Table 1). Therefore, the ascending or
descending trend of θi, j effectively represents exon inclu-
sion or exon skipping respectively.
Flocks in Figure 1b are small positive values rose as false
positive θ values in alternatively spliced gene 1 and 2.
They are caused by the randomness of simulations,
because the expression of alternatively spliced exons is
possible to be the median of expression of all exons in the
same gene. At the same time, other constitutive exons will
be considered as alternatively spliced exons by error. θ val-
ues of these flocks are higher than those of fake alterna-
tively spliced exons, but much less than true positives. As
to alternatively spliced gene 3 and 4 with mutually exclu-
sive splicing, positive and negative θ values exactly repre-
sent the pre-defined splicing pattern. Opposite θ values
compromised each other so that the average of θ is close
to zero.
Simulation 2
This simulation serves as a supplement to simulation 1 to
evaluate the performance of REMAS on small size sam-
ples. Most of the conditions were preserved except that the
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Table 1: Design of simulation 1 for evaluation
Gene ID Treatment Group Control Group
1 Exon 5~N (0, 1) All exons ~N (2.5,1), correlated
Exon 6~N (0, 1)
Others ~N (2.5, 1), correlated
2 Exon 5~N (0, 1) All exons ~N (1.5,1), correlated
Exon 6~N (0, 1)
Others ~N (1.5, 1), correlated
3 Exon 5~N (2.5, 1) Exon 5~N (0, 1)
Exon 6~N (0, 1) Exon 6~N (2.5, 1)
Others ~N (2.5, 1), correlated Others ~N (2.5, 1), correlated
4 Exon 5~N (1.5, 1) Exon 5~N (0, 1)
Exon 6~N (0, 1) Exon 6~N (1.5, 1)
Others ~N (1.5, 1), correlated Others ~N (1.5, 1), correlated
Exon 5 and Exon 6 are simulated as cassette exons in alternatively spliced gene 1 and 2, while they are defined as mutually exclusive exons in 
alternatively spliced gene 3 and 4.BMC Bioinformatics 2009, 10(Suppl 1):S18 http://www.biomedcentral.com/1471-2105/10/S1/S18
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sample size was reduced to 10 for each group. The same
procedure was repeated following simulation 1. REMAS
still showed high stability in selecting alternatively spliced
gene 1 and 3, but the rate of successfully selection of alter-
natively spliced gene 2 and 4 decreased (See Figure 2).
Optimized λ is set as 0.001 in five-fold cross-validation at
this simulation.
In order to make up the loss of capability, an iterative
selection strategy was introduced to improve the sensitiv-
ity of REMAS. The most significant alternatively spliced
gene was selected in iteration, and the other genes and
exons remained for the next selection. For example, alter-
natively spliced gene 1 and 3 and their exons are removed
in simulation 2 after the first iteration. As shown in Figure
3, gene 2 and 4 are significantly selected out in the second
round of simulation 2. Optimized λ equals to 0.5 in five-
fold cross-validation. Conclusively, this strategy provides
an effective measurement to maximally reduce the nega-
tive effect of small sample size.
Simulation 3
This simulation was designed to describe the coupled reg-
ulation of transcription and splicing when AS events arose
in the differentially expressed genes. It is challenging for
REMAS to accurately predict AS because complex regula-
tions result in a complicated data distribution. Simulated
exons are identical with simulation 1, while the overall
gene expression is set differently between two groups by
controlling the powers of normal distribution (see Table
2).
Taken optimized λ = 0.5 in five-fold cross-validation, sim-
ulation was repeated for 1000 times to select alternatively
spliced genes and exons. As shown in Figure 4a, four sim-
ulated genes undergoing AS could be selected robustly
every time. Figure 4b represents the property of θ for the
first 50 exons selected. The distribution of θ is same with
property of θ in simulation 1 as illustrated in Figure 1.
These results demonstrated that REMAS is robust enough
Selection frequency in the first iteration in simulation 2 Figure 2
Selection frequency in the first iteration in simula-
tion 2. Frequencies of the 50 genes selected by REMAS in 
simulation 2 are illustrated. The total number of selection is 
1000.
Results of simulation 1 Figure 1
Results of simulation 1. Panel 'a' shows frequencies of selection by REMAS for the 50 genes in simulation 1. Panel 'b' shows 
distribution of average values of θ for the first 50 exons in simulation 1. The total number of selection is 1000.BMC Bioinformatics 2009, 10(Suppl 1):S18 http://www.biomedcentral.com/1471-2105/10/S1/S18
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to identify AS even in condition of sophisticated regula-
tions.
Evaluation on real exon array data
A public available human colon cancer data including 20
paired healthy and tumour samples were used to evaluate
the performance of REMAS on real exon array data. Gar-
dina et al. had analyzed the data based on SI algorithm
and 189 putative AS events were predicted. Among them,
45 AS events have been validated by RT-PCR or literatures
[16].
Probesets of exon array can be classified into three types
according to their primary source and confidence (Gene-
Chip@ Exon Array Design Technical Note, Affymetrix).
"Core" probesets are supported by well-curated mRNA
sequences of RefSeq [21] and some other databases.
"Extended" and "full" probesets are designed based on
either low quality or predicted sequences. To minimize
the influence of noises, only "Core" probesets were
selected for evaluation. Selected with REMAS, alterna-
tively spliced genes were ranked by values of α. There are
57 overlapping alternatively spliced genes between top
500 genes identified by REMAS and predicted by SI algo-
rithm. Among the top ten genes in our ranking list, four of
them have been validated by RT-PCR. It is also remarkable
that 20 of 57 genes are validated by RT-PCR or supported
by literatures (see Table 3). Furthermore, alternatively
spliced exons were detected by θ to confirm their posi-
tions in gene structure. Twelve genes from Table 3 were
selected to show distribution of θ values for exons along
the gene (see Figure 5), which demonstrates that REMAS
can detect alternatively spliced genes and exons effec-
tively. For example, the 4th and 6th exon of COL6A3 gene
are cassette exons which have been validated by RT-PCR.
The  θ  values for both probeset 2605390 (Affymetrix
probeset ID) targeting the 4th exon and probeset 2605386
targeting the 6th exon are significantly prominent in our
results.
Discussion
We developed an improved regression model named
REMAS to select alternatively spliced genes and exons
from exon array data. Both simulation and real data anal-
ysis indicate that REMAS has convincing capability in
identification of AS events.
Although many splicing events deal with multiple exons,
the linear SI algorithm ignores relationships between
exons and identifies alternatively spliced exons individu-
Table 2: Design of simulation 3 for evaluation
Gene ID Treatment Group Control Group
1 Exon 5~N (0, 1) All exons ~N (1.5,1), correlated
Exon 6~N (0, 1)
Others ~N (2.5, 1), correlated
2 Exon 5~N (0, 1) All exons ~N (2.5,1), correlated
Exon 6~N (0, 1)
Others ~N (1.5, 1), correlated
3 Exon 5~N (2.5, 1) Exon 5~N (0, 1)
Exon 6~N (0, 1) Exon 6~N (1.5, 1)
Others ~N (2.5, 1), correlated Others ~N (1.5, 1), correlated
4 Exon 5~N (1.5, 1) Exon 5~N (0, 1)
Exon 6~N (0, 1) Exon 6~N (2.5, 1)
Others ~N (1.5, 1), correlated Others ~N (2.5, 1), correlated
The design of alternatively spliced exons is same with simulation 1, but the power of normal distribution is different between two sample groups to 
simulate the differential expression in gene level.
Selection frequency in the second iteration in simulation 2 Figure 3
Selection frequency in the second iteration in simula-
tion 2. Frequencies of the 48 genes selected by REMAS in 
simulation 2 after removing alternatively spliced gene 1 and 3. 
The total number of selection is 1000.BMC Bioinformatics 2009, 10(Suppl 1):S18 http://www.biomedcentral.com/1471-2105/10/S1/S18
Page 7 of 9
(page number not for citation purposes)
ally. For example, mutually exclusive exon is one of the
common AS patterns in eukaryotes. Regarding gene as an
assembly of exons, REMAS can select those correlated
exons in alternatively spliced gene in a single iteration (see
results of simulation and Figure 5). Furthermore, REMAS
can rank genes according to their potentials for AS. The
ranking is also considered as an important confident
index of prediction reliability.
Limitations also should be paid attention to our method.
Here we only focus on the linear regression model. It is
also possible to train a logistic regression model and per-
form the variable selection in the similar way. However,
the computation will be much heavy than linear regres-
sion. Up to now, we cannot address a reasonable conver-
gent threshold for AS detection in real data, because it is
difficult to estimate how many AS events occur in samples
in prior. When we are preparing our manuscript, Xing et
al. recently published a new method detecting AS from
exon array data with a high validation rate by RT-PCR[22].
The comparison between REMAS and this method and
evaluation with their validated data will be addressed in
our future works.
Conclusion
AS is difficult to be validated because genes undergoing
alternate splicing always express in specific conditions.
Therefore, well-validated exon array datasets are very
important for developing efficient methods. In despite of
these facts, REMAS is a valuable choice for identifying AS
events from exon array data with good performance and
some unique advantages.
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